Last reviewed · How we verify
Salovum
Salovum is a Small molecule drug developed by Henrik Lindman. It is currently in Phase 3 development.
Salovum is being studied in clinical trials for various conditions, including glioblastoma, cerebral metastases, meningioma, anal cancer, and head trauma. The trials are investigating the impact of Salovum and SPC flakes on brain tumor-induced edema.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Salovum |
|---|---|
| Sponsor | Henrik Lindman |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma (PHASE2)
- Antisecretory Factor In Severe Traumatic Brain Injury (PHASE2)
- Antisecretory Factor Glioblastoma Phase 2 (PHASE2, PHASE3)
- Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema (PHASE2)
- Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer (PHASE3)
- Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury (PHASE3)
- Role of Antisecretory Factor in Dihydropyrimidine Treatment of Colorectal Cancer (NA)
- Role of Antisecretory Factor in Curative Radiochemotherapy for Anal Carcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salovum CI brief — competitive landscape report
- Salovum updates RSS · CI watch RSS
- Henrik Lindman portfolio CI
Frequently asked questions about Salovum
What is Salovum?
Who makes Salovum?
What development phase is Salovum in?
Related
- Manufacturer: Henrik Lindman — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing